Sanofi
🇫🇷France
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
Artificial Intelligence (AI) in Biotechnology Market Industry
The AI in Biotechnology Market is projected to grow from USD 2.10 Bn in 2024 to USD 7.11 Bn by 2031, at a CAGR of 19%. Key opportunities include increased diagnostic accuracy, personalized therapies, revolutionized drug discovery, advanced genomic analytics, and integrated healthcare systems. Major players analyzed include AstraZeneca, Bristol-Myers Squibb, and Gilead Sciences Inc.
France: Oncovita appoints Stéphane Altaba as new CEO
Oncovita appoints Dr Stéphane Altaba as CEO, leveraging his 25 years of experience in pharmaceuticals and biotechnology. The company received €4.5m in funding under the France 2030 plan and completed a €3.5m fundraising round.
Understanding the Nuances of the RSV Maternal Vaccine and Monoclonal Antibody for the Protection of Infants
RSV causes severe disease in neonates, leading to hospitalizations. FDA-approved maternal RSV vaccine (Abrysvo, Pfizer) and monoclonal antibody (nirsevimab-alip, Beyfortus, Sanofi/Astra Zeneca) protect infants from severe RSV-related hospitalizations, with efficacy around 60-70%. The maternal vaccine is administered during pregnancy, while the monoclonal antibody is given at birth, both providing protection for the first 4-6 months.
Swiss pharma Roche bets big on obesity
Roche refocuses R&D on obesity, Alzheimer's, and other major diseases to align with healthcare budget demands and market potential, following the success of drugs like Ozempic and Wegovy.
Tolerance Bio: $17.2 Million (Seed) Raised For Increasing Healthspan By Adjusting ...
Tolerance Bio, a biopharmaceutical company focused on thymus function manipulation, closed a $17.2 million seed financing round. The company aims to develop iPSC-based cell therapies and pharmacological treatments for immune-mediated diseases, including cancer and autoimmunity. The technologies were developed by a team with extensive experience in biopharma, including former executives from Provention Bio and Celimmune.
FTC's watchdog role in pharma mergers: Road bumps and the way forward
The FTC's 2023 revised merger guidelines impact pharmaceutical industries with stricter HHI and market share requirements, emphasizing direct evidence of market dominance and ecosystem competition. The FTC scrutinizes pharmaceutical mergers for market concentration, innovation, and entry barriers, with ongoing investigations into Novo Nordisk/Catalent and AbbVie/Cerevel mergers. The EC investigates Zoetis for potential abuse of dominance post-merger, and the FTC challenges fraudulent patents to prevent market monopolization. Pharmaceutical companies are increasingly merging with biotech firms to offset patent expirations and enhance product portfolios.
Clesrovimab Shows Significant Reduction in RSV Infections, Hospitalizations in Infants
Clesrovimab (Merck) significantly reduced RSV-related infections and hospitalizations in infants, with a favorable safety profile, according to Phase IIb/III MK-1654-004 trial results presented at IDWeek 2024. The investigational monoclonal antibody showed potential as a single-dose preventive treatment for RSV in healthy and at-risk infants. Clesrovimab reduced RSV-associated hospitalizations by 84.2% and severe MALRI by 91.7% compared to placebo, with no treatment-related deaths reported.
The Interplay: Key Decisions at the Intersection of Antitrust and Life Sciences - September 2024
Novo Nordisk's lawsuit against DCA Pharmacy for selling unapproved Ozempic drugs proceeds. Sanofi and AstraZeneca support Teva's Orange Book defense. FTC supports FDA's biosimilars draft guidance. Par Pharma escapes price-fixing claims via bankruptcy. State AGs request Teva's broader price-fixing case to proceed first.
Merck antibody reduces RSV-related disease, hospitalizations in trial
Merck's experimental antibody drug, clesrovimab, significantly reduced RSV disease incidence by 60% and hospitalizations by 84% in infants, outperforming placebo in a Phase 2b/3 study. If approved, it would compete with Sanofi and AstraZeneca's Beyfortus, the only antibody drug cleared for all infants entering their first RSV season. Merck aims for U.S. approval by the 2025-2026 RSV season.
MSD mulls 2025/26 launch for RSV vaccine after Phase II/III win
MSD plans to launch its RSV vaccine, clesrovimab, by 2025-26 after positive Phase IIb/III trial results showing a 60% reduction in RSV-associated MALRI. Clesrovimab also reduced RSV-associated hospitalizations by 84.2% and LRTD hospitalizations by 90.9% over five months. The vaccine's main competitor, AstraZeneca and Sanofi's Beyfortus, is expected to dominate the market due to its first-to-market advantage.
© Copyright 2025. All Rights Reserved by MedPath